UK markets closed

Innate Pharma S.A. (IPHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.9000+0.2000 (+7.41%)
At close: 04:00PM EDT
Show:
Annual

Income statement

Currency in EUR. All numbers in thousands
Breakdown
ttm
31/12/2021
31/12/2020
31/12/2019
31/12/2018
Total revenue
12,110
12,110
56,833
68,973
79,892
Cost of revenue
-
-
3,042
45,158
-
Gross profit
-
-
53,791
23,815
-
Operating expenses
Research development
47,004
47,004
58,613
1,596
69,555
Selling general and administrative
15,991
15,991
26,066
49,581
19,251
Total operating expenses
59,937
59,937
72,338
50,868
74,746
Operating income or loss
-47,827
-47,827
-18,547
-27,053
5,146
Interest expense
312
312
341
204
102
Total other income/expenses net
2,330
2,330
-45,660
4,859
-2,143
Income before tax
-45,478
-45,478
-63,984
-20,759
2,718
Income tax expense
0
0
0
0
-333
Income from continuing operations
-45,478
-45,478
-63,984
-20,759
3,049
Net income
-52,809
-52,809
-63,984
-20,759
3,049
Net income available to common shareholders
-52,809
-52,809
-63,984
-20,759
3,049
Basic EPS
-
-
-0.81
-0.31
0.05
Diluted EPS
-
-
-0.81
-0.31
0.05
Basic average shares
-
-
78,935
66,908
58,777
Diluted average shares
-
-
78,935
66,908
58,777
EBITDA
-
-40,570
-6,846
-4,024
10,221